ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR) has been named as one of the 100
Best Medium Workplaces based on an independent survey by Fortune Magazine
and Great Place to Work®. The survey included more
than 52,000 employees at over 450 companies based in the United States.
Companies included on the list showed strong corporate culture, a
commitment to employee benefits, a deep engagement among employees, and
a clear sense of mission.
This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20161012005439/en/
Acorda Therapeutics, Inc. has been named as one of the 100 Best Medium Workplaces based on an independent survey by Fortune Magazine and Great Place to Work®. (Photo: Business Wire)
“We’re gratified to receive this recognition. Our associates have
established a culture that values trust, collaboration and open
communication. This culture is an extension of our mission to develop
therapies that improve the lives of people with neurological disorders,”
said Ron Cohen, M.D., Acorda's President and CEO. “Developing new,
life-changing medicines is an incredibly challenging undertaking, which
our associates embrace. Being able to come to work with like-minded
individuals, in a supportive, rewarding and fun environment, helps us to
stay focused on that mission.”
In addition to being named one of the Best Medium Workplaces, Acorda was
also recognized by Fortune and Great Place to Work in 2016 as one of the
Best Workplaces for Women (second year in a row), as well as Best
Workplaces for Baby Boomers and Best Workplaces for Millennials. The
Company has also been recognized as one of the Best Places to Work
in New York for six consecutive years by the Best Companies Group,
ranking 3rd in 2016 among employers with more than 250
associates. These recognitions highlight Acorda’s commitment to creating
an inclusive and diverse workplace that values the contributions of all
associates.
The Best Medium Workplaces list was determined by surveying employees on
factors such as their feelings on management’s credibility, the degree
of support for employees' personal and professional lives, employees’
overall job satisfaction, and sense of camaraderie. Fortune and Great
Place to Work also assessed corporate culture, salary and benefit
programs, hiring practices, internal communication, training,
recognition programs, and diversity efforts in determining the final
rankings.
For more information on careers at Acorda, please visit http://www.acorda.com/careers.
About Acorda Therapeutics
Founded in 1995, Acorda
Therapeutics is a biotechnology company focused on developing
therapies that restore function and improve the lives of people with
neurological disorders.
Acorda has an industry leading pipeline of novel neurological therapies
addressing a range of disorders, including Parkinson’s disease,
post-stroke walking difficulties, migraine, and multiple sclerosis.
Acorda markets three FDA-approved therapies, including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg.
For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statement
This press release includes forward-looking statements. All statements,
other than statements of historical facts, regarding management's
expectations, beliefs, goals, plans or prospects should be considered
forward-looking. These statements are subject to risks and uncertainties
that could cause actual results to differ materially, including: the
ability to complete the Biotie transaction on a timely basis; the
ability to realize the benefits anticipated from the Biotie and Civitas
transactions, among other reasons because acquired development programs
are generally subject to all the risks inherent in the drug development
process and our knowledge of the risks specifically relevant to acquired
programs generally improves over time; the ability to successfully
integrate Biotie’s operations and Civitas’ operations, respectively,
into our operations; we may need to raise additional funds to finance
our expanded operations and may not be able to do so on acceptable
terms; our ability to successfully market and sell
Ampyra (dalfampridine) Extended Release Tablets, 10 mg in the U.S.;
third party payers (including governmental agencies) may not reimburse
for the use of Ampyra or our other products at acceptable rates or at
all and may impose restrictive prior authorization requirements that
limit or block prescriptions; the risk of unfavorable results from
future studies of Ampyra or from our other research and development
programs, including CVT-301 or any other acquired or in-licensed
programs; we may not be able to complete development of, obtain
regulatory approval for, or successfully market CVT-301, any other
products under development, or the products that we will acquire when we
complete the Biotie transaction; the occurrence of adverse safety events
with our products; delays in obtaining or failure to obtain and maintain
regulatory approval of or to successfully market Fampyra outside of the
U.S. and our dependence on our collaborator Biogen in connection
therewith; competition; failure to protect our intellectual property, to
defend against the intellectual property claims of others or to obtain
third party intellectual property licenses needed for the
commercialization of our products; and failure to comply with regulatory
requirements could result in adverse action by regulatory agencies.
These and other risks are described in greater detail in our filings
with the Securities and Exchange Commission. We may not actually achieve
the goals or plans described in our forward-looking statements, and
investors should not place undue reliance on these statements.
Forward-looking statements made in this presentation are made only as of
the date hereof, and we disclaim any intent or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this presentation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161012005439/en/
Source: Acorda Therapeutics, Inc.